Beijing Dingcheng Taiyuan Biotechnology

Beijing Dingcheng Taiyuan Biotechnology is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the development of advanced cellular immunotherapies for solid tumors. The company leverages three core technology platforms: T-cell receptor-engineered T-cell (TCR-T) therapy, chimeric antigen receptor T-cell (CAR-T) therapy, and CAR-NK cell therapy. Its lead program, DCTY-T1301, is a TCR-T therapy targeting the NY-ESO-1 antigen and is currently in Phase 1 clinical development for synovial sarcoma and other solid malignancies. Dingcheng Taiyuan has built a robust pipeline targeting high-prevalence cancers in Asia, including hepatocellular carcinoma and gastric cancer, using antigens such as AFP and Claudin 18.2. The company operates integrated R&D and GMP-compliant manufacturing facilities to support its clinical trials and future commercialization efforts. Since its founding in 2014, it has secured significant venture capital funding to advance its mission of providing curative cell therapies for cancer patients.